Cardax

Cardax Depreciation & Amortization

The Depreciation & Amortization of Cardax (CDXI) as of Oct 18, 2026 is 34,500.00 USD. In the previous year, Depreciation & Amortization was 39,600.00 USD — a change of -12.88% (lower).

Depreciation & Amortization

34,500.00USD

YoY

-12.88%

Last updated:

Depreciation & Amortization of Cardax is 2020 34,500.00 USD. Depreciation & Amortization of Cardax was 2019 39,600.00 USD. It decreases by -12.88% lower compared to the previous year.

The Cardax Depreciation & Amortization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Depreciation & Amortization
Date
Depreciation & Amortization
Jan 1, 2015
23,800.00 USD
Jan 1, 2016
29,100.00 USD
Jan 1, 2017
29,400.00 USD
Jan 1, 2018
30,600.00 USD
Jan 1, 2019
39,600.00 USD
Jan 1, 2020
34,500.00 USD
The Cardax Depreciation & Amortization history
YEARDepreciation & AmortizationYoY
34,500.00USD-12.88%
39,600.00USD+29.41%
30,600.00USD+4.08%
29,400.00USD+1.03%
29,100.00USD+22.27%
23,800.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cardax Stock analysis

What does Cardax do? Cardax Inc, a development stage biopharmaceutical company based in Honolulu, Hawaii, focuses on developing pharmaceuticals for chronic diseases driven by inflammation. The company has 10 full-time employees and went public via an IPO on January 30, 2012. Cardax is currently developing two pre-clinical pharmaceutical candidates: CDX-101 and CDX-301. CDX-101 is a proprietary astaxanthin prodrug designed to deliver astaxanthin to the bloodstream following oral administration. Astaxanthin is a naturally occurring molecule known for its anti-inflammatory properties, supporting cardiovascular health, metabolic health, liver health, joint health, and longevity. CDX-301 is a pharmaceutical candidate for macular degeneration, utilizing zeaxanthin, which accumulates in the human eye through a retinal receptor to protect against blue light, oxidative damage, and inflammation associated with macular degeneration. The company's headquarters are located in Honolulu, and it operates within the Health Care sector, specifically in the Pharmaceuticals industry. Cardax Inc's website is https://cardaxpharma.com/. The company is seeking to monetize its pre-clinical candidates, CDX-101 and CDX-301, as it advances its development pipeline. No additional details about the company's financials, specific acquisition history, or other product names are provided in the available information. Cardax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cardax stock

Depreciation & Amortization of Cardax is 34,500.00 USD in 2020.

Depreciation & Amortization of Cardax changed from 39,600.00 USD to 34,500.00 USD, representing a -12.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Depreciation & Amortization Cardax since 2006 – with annual values, charts, and detailed analysis.

Depreciation & Amortization represents the allocation of the cost of tangible and intangible assets over their useful lives.

Depreciation & Amortization's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Depreciation & Amortization's Cardax historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Cardax

All Key Metrics — Cardax